These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 38414479)

  • 1. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.
    Sosnowska B; Stepinska J; Mitkowski P; Bielecka-Dabrowa A; Bobrowska B; Budzianowski J; Burchardt P; Chlebus K; Dobrowolski P; Gasior M; Jankowski P; Kubica J; Mickiewicz A; Mysliwiec M; Osadnik T; Prejbisz A; Rajtar-Salwa R; Wita K; Witkowski A; Gil R; Banach M
    Arch Med Sci; 2024; 20(1):8-27. PubMed ID: 38414479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.
    Chan DC; Watts GF; Coll B; Wasserman SM; Marcovina SM; Barrett PHR
    J Am Heart Assoc; 2019 Apr; 8(7):e011781. PubMed ID: 30897995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Polynesian-specific SLC22A3 variant associates with low plasma lipoprotein(a) concentrations independent of apo(a) isoform size in males.
    Wang Q; McCormick S; Leask MP; Watson H; O'Sullivan C; Krebs JD; Hall R; Whitfield P; Merry TL; Murphy R; Shepherd PR
    Biosci Rep; 2024 Jul; 44(7):. PubMed ID: 38896441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry.
    Sosnowska B; Lewek J; Adach W; Mierczak K; Bielecka-Dąbrowa A; Szosland K; Zygmunt A; Dąbrowski J; Banach M
    Prog Cardiovasc Dis; 2024; 86():54-61. PubMed ID: 39191356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors.
    Blanchard V; Chemello K; Hollstein T; Hong-Fong CC; Schumann F; Grenkowitz T; Nativel B; Coassin S; Croyal M; Kassner U; Lamina C; Steinhagen-Thiessen E; Lambert G
    Cardiovasc Res; 2022 Jul; 118(9):2103-2111. PubMed ID: 34314498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort.
    Matveyenko A; Matienzo N; Ginsberg H; Nandakumar R; Seid H; Ramakrishnan R; Holleran S; Thomas T; Reyes-Soffer G
    J Lipid Res; 2023 Mar; 64(3):100336. PubMed ID: 36706955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study.
    Tsimikas S; Clopton P; Brilakis ES; Marcovina SM; Khera A; Miller ER; de Lemos JA; Witztum JL
    Circulation; 2009 Apr; 119(13):1711-9. PubMed ID: 19307470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men.
    Paultre F; Pearson TA; Weil HF; Tuck CH; Myerson M; Rubin J; Francis CK; Marx HF; Philbin EF; Reed RG; Berglund L
    Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2619-24. PubMed ID: 11116062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype.
    Guo HC; Chapman MJ; Bruckert E; Farriaux JP; De Gennes JL
    Atherosclerosis; 1991 Jan; 86(1):69-83. PubMed ID: 1829609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
    Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
    Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) and its impact on cardiovascular disease - the Polish perspective: design and first results of the Zabrze-Lipoprotein(a) Registry.
    Dyrbuś K; Mędrala Z; Konsek K; Nowowiejska-Wiewióra A; Trzeciak P; Skrzypek M; Cieśla D; Banach M; Gąsior M
    Arch Med Sci; 2024; 20(4):1069-1076. PubMed ID: 39439677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant differentiation in the apolipoprotein(a)/lipoprotein(a) trait between chimpanzees from Western and Central Africa.
    Noureen A; Ronke C; Khalifa M; Halbwax M; Fischer A; André C; Atencia R; Garriga R; Mugisha L; Ceglarek U; Thiery J; Utermann G; Schmidt K
    Am J Primatol; 2017 Sep; 79(9):. PubMed ID: 28671714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small apolipoprotein(a) isoforms may predict primary patency following peripheral arterial revascularization.
    Pavlyha M; Hunter M; Nowygrod R; Patel V; Morrissey N; Bajakian D; Li Y; Reyes-Soffer G
    medRxiv; 2024 Mar; ():. PubMed ID: 38562737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol.
    Clarke SL; Huang RDL; Hilliard AT; Levin MG; Sharma D; Thomson B; Lynch J; Tsao PS; Gaziano JM; Assimes TL;
    Eur J Prev Cardiol; 2024 Aug; ():. PubMed ID: 39158116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders.
    Solnica B; Sygitowicz G; Sitkiewicz D; Jóźwiak J; Kasperczyk S; Broncel M; Wolska A; Odrowąż-Sypniewska G; Banach M
    Arch Med Sci; 2024; 20(2):357-374. PubMed ID: 38757022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions.
    Mitkowski P; Witkowski A; Stępińska J; Banach M; Jankowski P; Gąsior M; Wita K; Bartuś S; Burchardt P; Farkowski MM; Gierlotka M; Gil R; Leszek P; Sterliński M; Szymański P; Tajstra M; Tycińska A; Wojakowski W
    Kardiol Pol; 2023; 81(7-8):818-823. PubMed ID: 37489830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) particle number assay without error from apolipoprotein(a) size isoforms.
    Contois JH; Nguyen RA; Albert AL
    Clin Chim Acta; 2020 Jun; 505():119-124. PubMed ID: 32113814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a) and apolipoprotein(a) in a New World monkey, the common marmoset (Callithrix jacchus). Association of variable plasma lipoprotein(a) levels with a single apolipoprotein(a) isoform.
    Guo HC; Michel JB; Blouquit Y; Chapman MJ
    Arterioscler Thromb; 1991; 11(4):1030-41. PubMed ID: 1829630
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.